These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 16848689)

  • 41. New Concepts in Dopamine D
    Urs NM; Peterson SM; Caron MG
    Biol Psychiatry; 2017 Jan; 81(1):78-85. PubMed ID: 27832841
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
    Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
    Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.
    Nakajima S; Uchida H; Bies RR; Caravaggio F; Suzuki T; Plitman E; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Mamo DC; Graff-Guerrero A
    Schizophr Bull; 2016 Jan; 42(1):212-9. PubMed ID: 26221049
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
    Tadori Y; Kikuchi T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment.
    Urigüen L; García-Fuster MJ; Callado LF; Morentin B; La Harpe R; Casadó V; Lluis C; Franco R; García-Sevilla JA; Meana JJ
    Psychopharmacology (Berl); 2009 Oct; 206(2):313-24. PubMed ID: 19652957
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability.
    Amato D; Vernon AC; Papaleo F
    Neurosci Biobehav Rev; 2018 Feb; 85():146-159. PubMed ID: 28970021
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.
    Kapur S; Zipursky R; Jones C; Remington G; Houle S
    Am J Psychiatry; 2000 Apr; 157(4):514-20. PubMed ID: 10739409
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Central D1- and D2-receptor occupancy during antipsychotic drug treatment.
    Wiesel FA; Farde L; Nordström AL; Sedvall G
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):759-67. PubMed ID: 1981395
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanism of new antipsychotic medications: occupancy is not just antagonism.
    Grunder G; Carlsson A; Wong DF
    Arch Gen Psychiatry; 2003 Oct; 60(10):974-7. PubMed ID: 14557141
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and pharmacological evaluation of 11-(1,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-5H-dibenzo[b,e][1,4]diazepines with clozapine-like receptor occupancy at dopamine D
    Watanabe H; Ishida K; Yamamoto M; Horiguchi M; Isobe Y
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127563. PubMed ID: 32976928
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
    Tauscher J; Küfferle B; Asenbaum S; Fischer P; Pezawas L; Barnas C; Tauscher-Wisniewski S; Brücke T; Kasper S
    Psychopharmacology (Berl); 1999 Jan; 141(2):175-81. PubMed ID: 9952042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dopamine receptors in the brains of schizophrenia patients: a meta-analysis of the findings.
    Kestler LP; Walker E; Vega EM
    Behav Pharmacol; 2001 Sep; 12(5):355-71. PubMed ID: 11710751
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypothesis testing: is clozapine's superior efficacy dependent on moderate D2 receptor occupancy?
    Carpenter WT; Zito JM; Vitrai J; Volavka J
    Biol Psychiatry; 1998 Jan; 43(2):79-83. PubMed ID: 9474440
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Schizophrenia model of elevated D2(High) receptors: haloperidol reverses the amphetamine-induced elevation in dopamine D2(High).
    Seeman P
    Schizophr Res; 2009 Apr; 109(1-3):191-2. PubMed ID: 19171464
    [No Abstract]   [Full Text] [Related]  

  • 56. Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis.
    Seeman P; Guan HC
    Eur J Pharmacol; 2007 Feb; 557(2-3):151-3. PubMed ID: 17157291
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways.
    Sakai K; Gao XM; Hashimoto T; Tamminga CA
    Synapse; 2001 Feb; 39(2):152-60. PubMed ID: 11180502
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action.
    Kapur S; McClelland RA; VanderSpek SC; Wadenberg ML; Baker G; Nobrega J; Zipursky RB; Seeman P
    Neuroreport; 2002 May; 13(6):831-5. PubMed ID: 11997696
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.
    Takano A; Suhara T; Ikoma Y; Yasuno F; Maeda J; Ichimiya T; Sudo Y; Inoue M; Okubo Y
    Int J Neuropsychopharmacol; 2004 Mar; 7(1):19-26. PubMed ID: 14764214
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dopamine D2 heteroreceptor complexes and their receptor-receptor interactions in ventral striatum: novel targets for antipsychotic drugs.
    Fuxe K; Borroto-Escuela DO; Tarakanov AO; Romero-Fernandez W; Ferraro L; Tanganelli S; Perez-Alea M; Di Palma M; Agnati LF
    Prog Brain Res; 2014; 211():113-39. PubMed ID: 24968778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.